Navigating the Shifting Terrain of Diffuse Large B-Cell Lymphoma Treatment: Insights for Early-Career Physicians Dr Kami Maddocks advises early-career physicians regarding the evolution of DLBCL ...

Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper ...

Kinase Inhibitors These drugs block certain enzymes that control cell growth ... relative survival rate for stage 4 Hodgkin lymphoma is 81 percent, and 64 percent for stage 4 non-Hodgkin lymphoma.

Moreover, research has highlighted the poor prognosis associated ... Diffuse Large B-Cell Lymphoma (DLBCL): A fast-growing type of non-Hodgkin lymphoma that affects B cells, which are a type ...

Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...

Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials, the fifth type of cancer the drug has been shown to treat.

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...

Laurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

NEW DELHI: India’s first global CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL), a kind of blood cancer that affects the lymphatic system, has been launched in the country ...